top of page

ACG

h.o.l.M.E.S.

Automated Clinical Guidelines

dipeptidyl.jpg
Dipeptidyl Peptidase 4 Inhibitors

Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class.  Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke... Wikipedia

 

Manufacturer's Website: Nesina                                                                                                                                             Average retail cost: $520/30 tabs

nesina.jpg
Nesina (alogliptin)
* Prices reflect U.S. average retail price

Linagliptin (INN, previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2... Wikipedia

 

Manufacturer's Website: Tradjenta                                                                                                                                     Average retail cost: $511/30 tabs

tradjenta.jpg
Tradjenta (linagliptin)

Sitagliptin (INN; marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2... Wikipedia

 

Manufacturer's Website: Januvia                                                                                                                                            Average retail cost: $729/30 tabs

januvia.png
Januvia (sitagliptin)

Discontinued by manufacturer

onglyza.jpg
Onglyza (saxagliptin)
bottom of page